Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABA B R Antibodies: Implications for Return to Driving.
Anna RadaAnne HagemannCharlotte Aaberg PoulsenTobias BaumgartnerTimea BerkiMorten BlaabjergJuliette BrennerJeffrey W BrittonAndrew ChristianaNicolás Lundahl Ciano-PetersenYvette CrijnenMartin ElišákAntonio FarinaAlec R FriedmanZsófia HaydenJulien HébertMartin HoltkampZhen HongJerome HonnoratMaria Ilyas-FeldmannSarosh R IraniStjepana KovacPetr MarusicSergio Muñiz-CastrilloSudarshini RamanathanKelsey M SmithClaude SteriadeChristine StrippelRainer SurgesMaarten J TitulaerChristopher E UyJuna M de VriesChristian G BienUlrich SpechtPublished in: Neurology(R) neuroimmunology & neuroinflammation (2024)
Taking a <20% recurrence risk within 12 months as sufficient, patients with NMDAR-AIE and LGI1-AIE could be considered eligible for noncommercial driving after having been seizure-free for 3 months.